Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Last Updated on: 24 February, 2024|Author: Getaka | Social: X Twitter Profile

Fundamental Analysis of Ortin Laboratories Ltd

About the Company - Ortin Laboratories Ltd

Ortin Laboratories Ltd. is a Public Limited Listed company incorporated on 27/10/1986 and has its registered office in the State of Andhra Pradesh, India. Company’s Corporate Identification Number(CIN) is L24110TG1986PLC006885 and registration number is 006885. Currently company belongs to the Industry of Pharmaceuticals. Company’s Total Operating Revenue is Rs. 8.23 Cr. and Equity Capital is Rs. 8.13 Cr. for the Year ended 31/03/2022.
PharmaceuticalsD. No. 1-8-B4, Ground Floor, F3 HIG, Block-4, Street No.3, Hyderabad Telangana
NamePosition Held
Mr. Murali Krishna RayaproluChairman & Ind.Director
Mr. S Murali Krishna MurthyManaging Director
Mr. S Srinivas KumarWhole Time Director
Mr. S Balaji VenkateswarluNon Executive Director
Mr. B Gopal ReddyIndependent Director
Ms. Pottur SujathaIndependent Director

Ortin Laboratories Ltd. Share Price Update

Share PriceValue
Previous Day₹21.30

Basic Stock Data of Ortin Laboratories Ltd

Market Cap 16.9 Cr.
Current Price 20.8
High / Low30.4/16.2
Stock P/E
Book Value 12.0
Dividend Yield0.00 %
ROCE1.80 %
ROE0.64 %
Face Value 10.0

Data Source:

Competitors of Ortin Laboratories Ltd

Stock NameMarket CapCurrent PriceHigh / LowStock P/EBook ValueDividend YieldROCEROEFace Value
Astrazeneca Pharma India Ltd 13,758 Cr. 5,5037,221/3,09886.3 2620.29 %30.9 %23.0 % 2.00
SMS Lifesciences India Ltd 178 Cr. 588707/46464.1 5530.26 %7.92 %6.12 % 10.0
Panacea Biotec Ltd 1,003 Cr. 164202/107 1380.00 %10.3 %10.9 % 1.00
Beta Drugs Ltd 1,259 Cr. 1,3101,595/60036.2 1480.00 %33.9 %28.6 % 10.0
Bafna Pharmaceuticals Ltd 220 Cr. 92.9126/77.019.5 34.80.00 %15.9 %16.4 % 10.0
Industry Average82.6 Cr170.1841.22227.160.11%19.78%17%6.6

Ortin Laboratories Ltd Quarterly Results

MonthSep 2020Dec 2020Mar 2021Jun 2021Sep 2021Dec 2021Mar 2022Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023
Operating Profit3.812.160.210.370.290.01-0.140.21-0.220.62-0.030.18-0.90
OPM %4.98%4.17%11.93%18.69%12.66%0.60%-5.71%8.02%-27.85%52.99%-2.01%11.46%-333.33%
Other Income0.
Profit before tax2.440.890.000.120.07-0.11-0.610.04-0.380.45-0.180.01-1.11
Tax %13.11%32.58%25.00%28.57%18.18%24.59%1,150.00%121.05%0.00%5.56%0.00%-1.80%
Net Profit2.120.600.800.090.05-0.09-0.45-0.430.080.46-0.180.02-1.12
EPS in Rs1.250.360.980.110.06-0.11-0.55-0.530.100.57-0.220.02-1.38

Ortin Laboratories Ltd Quarterly Chart

Ortin Laboratories Ltd Profit & Loss

MonthMar 2012Mar 2013Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023TTM
Operating Profit6.936.576.106.495.895.455.416.685.701.240.380.53-0.13
OPM %7.66%8.79%9.10%10.76%9.39%8.85%6.79%3.99%2.89%15.20%4.62%8.83%-2.89%
Other Income0.260.240.810.000.570.320.450.
Profit before tax2.581.861.681.331.391.130.681.840.710.13-0.53-0.11-0.83
Tax %50.78%41.40%29.17%32.33%41.01%55.75%0.00%30.43%181.69%-623.08%24.53%18.18%
Net Profit1.
EPS in Rs0.760.640.700.530.490.300.400.76-0.331.17-0.49-0.11-1.01
Dividend Payout %66.17%38.85%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%

Ortin Laboratories Ltd Profit & Loss Yearly Chart

Ortin Laboratories Ltd Growth

Compounded Sales Growth
10 Years:-22%
5 Years:-40%
3 Years:-69%
Compounded Profit Growth
10 Years:%
5 Years:%
3 Years:23%
Stock Price CAGR
10 Years:%
5 Years:9%
3 Years:-13%
1 Year:-7%
Return on Equity
10 Years:3%
5 Years:1%
3 Years:1%
Last Year:-1%

Ortin Laboratories Ltd Balance Sheet

MonthMar 2012Mar 2013Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Sep 2023
Equity Capital16.9416.9416.9416.9416.9416.9416.9416.9416.948.
Other Liabilities49.8034.8031.9323.8721.2220.7932.2460.5373.132.973.613.892.46
Total Liabilities83.0673.5072.5767.2765.3461.5373.66105.09116.5221.2620.7121.2018.23
Fixed Assets23.8524.7723.9021.8321.6320.6920.0321.2922.4514.3814.2113.9613.84
Other Assets59.1848.7048.6445.4143.6840.4253.1583.1993.576.456.076.813.96
Total Assets83.0673.5072.5767.2765.3461.5373.66105.09116.5221.2620.7121.2018.23

Ortin Laboratories Ltd Reserves and Borrowings Chart

Ortin Laboratories Ltd Cash Flow

MonthMar 2012Mar 2013Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023
Cash from Operating Activity 0.29-1.66-1.76-1.380.521.941.566.523.3018.032.15-0.25
Cash from Investing Activity -2.23-2.08-0.020.22-0.86-1.26-0.90-3.27-3.090.07-0.130.01
Cash from Financing Activity 1.794.700.971.730.27-0.820.07-2.89-1.33-9.86-0.470.90
Net Cash Flow-0.150.96-0.810.58-0.07-0.140.730.37-

Ortin Laboratories Ltd Financial Efficiency Indicators

MonthMar 2012Mar 2013Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023
Debtor Days176.97134.10116.69103.7753.1390.35100.1582.4368.71174.90143.69208.05
Inventory Days60.92102.80162.92192.30148.72158.21152.21100.07117.80169.10136.29279.94
Days Payable250.38199.45197.95151.0924.82108.10143.09145.12155.80123.8261.88166.89
Cash Conversion Cycle-12.5037.4581.66144.97177.04140.45109.2837.3830.70220.17218.10321.10
Working Capital Days35.5556.9486.07118.60104.81126.92108.6848.9438.38158.7986.93168.51
ROCE %22.50%14.90%13.08%12.07%10.92%9.57%9.44%11.77%8.94%3.24%1.58%1.80%

Ortin Laboratories Ltd Financial Efficiency Indicators Chart

Ortin Laboratories Ltd Share Holding Pattern

MonthDec 2020Mar 2021Jun 2021Sep 2021Dec 2021Mar 2022Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023
No. of Shareholders7,3637,29712,30211,94712,81912,66212,57112,44912,78112,58512,18111,836

Ortin Laboratories Ltd Shareholding Pattern Chart

No. of Ortin Laboratories Ltd Shareholders

This stock is not held by any mutual fund

Ortin Laboratories Ltd ROCE Trend

Ortin Laboratories Ltd EPS Trend

Ortin Laboratories Ltd Key Financial Ratios

MonthMar 12
Basic EPS (Rs.)2.73
Diluted EPS (Rs.)2.73
Cash EPS (Rs.)3.59
Book Value[Excl.RevalReserv]/Share (Rs.)14.47
Book Value[Incl.RevalReserv]/Share (Rs.)14.47
Revenue From Operations / Share (Rs.)50.63
PBDIT / Share (Rs.)6.99
PBIT / Share (Rs.)6.13
PBT / Share (Rs.)4.20
Net Profit / Share (Rs.)2.73
NP After MI And SOA / Share (Rs.)2.73
PBDIT Margin (%)13.81
PBIT Margin (%)12.10
PBT Margin (%)8.30
Net Profit Margin (%)5.38
NP After MI And SOA Margin (%)5.38
Return on Networth / Equity (%)18.85
Return on Capital Employeed (%)34.77
Return On Assets (%)5.67
Long Term Debt / Equity (X)0.11
Total Debt / Equity (X)0.58
Asset Turnover Ratio (%)1.26
Current Ratio (X)1.11
Quick Ratio (X)0.82
Inventory Turnover Ratio (X)6.59
Interest Coverage Ratio (X)3.63
Interest Coverage Ratio (Post Tax) (X)2.42
Enterprise Value (Cr.)62.39
EV / Net Operating Revenue (X)0.72
EV / EBITDA (X)5.27
MarketCap / Net Operating Revenue (X)0.56
Price / BV (X)1.97
Price / Net Operating Revenue (X)0.56

Ortin Laboratories Ltd Profitability Ratios (%)

Ortin Laboratories Ltd Liquidity Ratios

Ortin Laboratories Ltd Liquidity Ratios (%)

Ortin Laboratories Ltd Interest Coverage Ratios (%)

Ortin Laboratories Ltd Valuation Ratios

Fair Value / Intrinsic Value of Ortin Laboratories Ltd

Fair Value: ₹1.18

The stock is overvalued by 94.35% compared to the current price ₹20.8

*Investments are subject to market risks

Strength and Weakness of Ortin Laboratories Ltd

  1. The company has shown consistent growth in sales (68.32 cr) and profit (0.91 cr) over the years.
  1. The stock is trading at a high valuation with an average P/B ratio of 6.13 and average Dividend Yield of 12.10%.
  2. The stock has a low average ROCE of 9.98%, which may not be favorable.
  3. The stock has a high average Working Capital Days of 94.93, which may not be favorable.
  4. The stock has a high average Cash Conversion Cycle of 125.48, which may not be favorable.
  5. The company has higher borrowings (14.67) compared to reserves (4.84), which may suggest financial risk.

Should I Buy Ortin Laboratories Ltd?

  • Considering various financial indicators, investors might exercise caution regarding investment in Ortin Laboratories Ltd:
    1. Net Profit Margin: 5.38%
      • Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
    2. ROCE: 34.77% (Industry Average ROCE: 12.66%)
      • ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
    3. Interest Coverage Ratio (Post Tax): 2.42
      • Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
    4. Quick Ratio: 0.82
      • Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
    5. ✓ Stock P/E of N/A (Industry average Stock P/E: 28.4)
      • Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
    6. ✓ Total Debt / Equity: 0.58
      • Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
    The current analysis suggests exercising caution. It's advisable to conduct further research or consult with financial experts before considering any investment.

About the Author

Author Avatar

Getaka, CFA, a financial analyst with 15 years of experience in the industry. Getaka holds an MBA degree and the Chartered Financial Analyst designation, demonstrating his profound understanding of financial analysis and investment management. Throughout his career, he has conducted numerous financial analyses and due diligence processes for companies in the industry, and has a strong track record of identifying key trends and opportunities. He leverages his expertise to deliver a thorough financial analysis of a company, encompassing its financial performance, key ratios, future prospects, and risks. Getaka is committed to providing accurate, reliable, and trustworthy information to help readers make informed decisions about their finances and investments.

Disclaimer: This article is for informational purposes only and should not be construed as financial advice. The author is not a SEBI registered financial advisor and does not have any vested interest in Ortin Laboratories Ltd. Investors are advised to conduct their own due diligence and consult with a financial professional before making any investment decisions. The information provided in this article is based on publicly available data and the author's analysis, but it may not be comprehensive or up-to-date. The author and are not responsible for any errors or omissions in the content. This article is not intended to promote any particular investment strategy or recommendation, and readers should consult with their own financial advisors before making any investment decisions. Data Source: NSE